Anemia in Non-Dialysis-Dependent CKD Patients Characterized
The condition is present in more than half of Medicare patients with stage 3-5 chronic kidney disease.
The condition is present in more than half of Medicare patients with stage 3-5 chronic kidney disease.
Sparsentan could become the first FDA-approved medication for the focal segmental glomerularsclerosis.
In a study, 94.1% of total PTx patients had improvement of bone mineral density at their most affected site.
Pending future research, patients should avoid taking more than 120 mg per day.
Surgery decreased the risk of death from any cause by 32% compared with usual treatment.
Just 6.7% of patients had target levels of calcium, phosphorus, and parathyroid hormone a year after surgery.
More patients treated with MWA plus calcitriol reached iPTH levels below 150 pg/mL: 23.33% vs 8.54%.
Their risk of the rare but life-threatening condition is twice as high as in hemodialysis patients.
Studies also link kidney stone development to osteoporosis and proton pump inhibitor use.
Sodium zirconium cyclosilicate treatment for 12 months had no clinically meaningful effects on systolic or diastolic pressure, study finds.